EUCTR2016-001560-11-FI进行中（未招募）1 期
A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma - SPIRIT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,406
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients completing a prior Phase 3 study of QAW039:
- •- Informed consent and assent (if applicable).
- •-Completion of the Treatment Period (on blinded study drug) of a prior Phase 3 study of QAW039.
- •-Patient is able to safely continue into the study as judged by the investigator.
- •Patients who have not previously participated in a study of QAW039:
- •-Written informed consent.
- •-Male and female patients aged =12 years.
- •-A diagnosis of asthma, uncontrolled on GINA 3/4/5 asthma medication. -Evidence of airway reversibility or airway hyper- reactivity.
- •-FEV1 =85% of the predicted normal value.
- •-An ACQ score =1.5 prior to entering the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 80
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2085
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 241
排除标准
- •Patients completing a prior phase 3 study of QAW039:
- •- Pregnant or nursing (lactating) women.
- •- Women of child-bearing potential unless they are using basic methods of contraception during dosing of study drug
- •- Patients who did not complete the Treatment Period on blinded study drug of the prior QAW039 study they participated in.
- •- Inability to comply with all study requirements.
- •- Patient who experienced a serious and drug-related AE in the prior QAW039 study they participated in.
- •Patients who have not previously participated in a study of QAW039:
- •-Use of other investigational drugs within 5 half-lives of study entry, or within 30
- •days, whichever is longer.
- •-Subjects who have participated in another trial of QAW039.
- •-A QTcF (Fridericia) =450 msec (male) or =460 msec (female).
- •-History of malignancy with the exception of local basal cell carcinoma of the skin.
- •-Pregnant or nursing (lactating) women.
- •-Serious co-morbidities.
- •-Patients on greater than 20 mg of simvastatin
研究者
相似试验
进行中（未招募）
1 期
Study of safety of QAW039 in patients (= 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapyMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001560-11-FRovartis Pharma AG2,344
进行中（未招募）
1 期
Study of safety of QAW039 in patients (= 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapyMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001560-11-HUovartis Pharma AG2,406
进行中（未招募）
1 期
Study of safety of QAW039 in patients (= 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapyAsthmaEUCTR2016-001560-11-PLovartis Pharma AG2,406
进行中（未招募）
3 期
A Study to review the Effectiveness and Safety of QAW039 in Patients With Severe Asthma who are Inadequately Controlled With Standard of Care Treatment.CTRI/2018/01/011183ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Study of safety of QAW039 in patients (= 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapyMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001560-11-GRovartis Pharma AG2,344